Publication date: Jul 15, 2023
With BCG revaccination, an average yearly investment of $67 per dose saved $43 million per year over 2025-2050. The cost was $656 million, considerably lower than with the M72/AS01E, averting 29 million DALYs. This would push up cases and deaths by ~5 million and ~ 970,000, respectively. As recently as 2021, there were almost three million cases in the country, with over 500,000 deaths. An earlier trial, when data from uninfected participants at the time of BCG vaccination, reported 36% protective efficacy. It is not known if M72/AS01E works well in uninfected individuals or if BCG revaccination protects against disease in adults. *Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
| Concepts | Keywords |
|---|---|
| Accounting | As01e |
| Spanner | Bcg |
| Tuberculosis | Cost |
| Deaths | |
| Dose | |
| Effective | |
| India | |
| M72 | |
| Period | |
| Revaccination | |
| Tuberculosis | |
| Vaccination | |
| Vaccine | |
| Vaccines | |
| Year |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | BCG vaccine |
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | coronavirus disease 2019 |
| drug | DRUGBANK | Spinosad |
| drug | DRUGBANK | Pentaerythritol tetranitrate |
| disease | MESH | infection |